Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $20.95 USD
Change Today +0.43 / 2.10%
Volume 331.0K
KPTI On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

karyopharm therapeutics inc (KPTI) Snapshot

Open
$20.43
Previous Close
$20.52
Day High
$21.67
Day Low
$20.09
52 Week High
12/8/14 - $49.01
52 Week Low
07/30/15 - $18.89
Market Cap
747.8M
Average Volume 10 Days
354.8K
EPS TTM
$-2.69
Shares Outstanding
35.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KARYOPHARM THERAPEUTICS INC (KPTI)

karyopharm therapeutics inc (KPTI) Related Bloomberg News

View More Bloomberg News

karyopharm therapeutics inc (KPTI) Related Businessweek News

No Related Businessweek News Found

karyopharm therapeutics inc (KPTI) Details

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company’s lead drug candidate, Selinexor, a novel selective inhibitor of nuclear export (SINE) compounds that specifically blocks XPO1 cargo binding is in Phase II clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise Topical SINE compound, which has completed preclinical trial for the treatment of wound healing; KPT-335, an oral SINE compound for viral indications; KPT-350 and related SINE compounds for the treatment of inflammatory and autoimmune indications; PAK4 Inhibitors for the treatment of oncology; and Verdinexor, an oral SINE compound that is in Phase 2b clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is headquartered in in Newton, Massachusetts.

71 Employees
Last Reported Date: 03/13/15
Founded in 2008

karyopharm therapeutics inc (KPTI) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $440.0K
Co-Founder, Co-Chairman of Scientific Advisor...
Total Annual Compensation: $385.0K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $129.4K
Executive Vice President of Worldwide Develop...
Total Annual Compensation: $64.2K
Compensation as of Fiscal Year 2014.

karyopharm therapeutics inc (KPTI) Key Developments

Karyopharm Therapeutics Inc. Announces Positive Data from Phase Ib B-Cell Lymphoma Study

Karyopharm Therapeutics Inc. has announced positive data from an ongoing Phase Ib clinical trial with selinexor, an oral selective inhibitor of nuclear export/SINE compound in patients with diffuse large B-cell lymphoma, or DLBCL. In an ongoing Phase Ib company-sponsored clinical trial evaluating the activity of single-agent selinexor (doses of 3-80mg/m) in heavily pre-treated patients with diffuse large B-cell lymphoma (DLBCL), selinexor demonstrated a 43% overall response rate (partial response or better) in patients on study greater than one month, and a 31% overall response rate across all doses in the intention to treat population, with a median duration of response (DOR) of greater than nine months. Similar responses were observed in both GCB and non-GCB subtypes. The median overall survival (OS) and progression free survival (PFS) were 4.6 months and 1.7 months, respectively, for the entire study. In patients with a response to selinexor (N=12), the median OS was greater than 10 months (median not reached) and PFS was 24 months, significantly longer than those without a response (N=27; OS 3.5 months, PFS 1.2 months). Adverse events were manageable with standard supportive care and clinically significant cumulative toxicities were not observed, with several patients remaining on selinexor for more than one year. Initial data from the ongoing Selinexor AraC Idarubicin Leukemia, or "SAIL," study, an investigator-sponsored Phase II clinical trial of selinexor with intensive chemotherapy (idarubicin and cytosine arabinoside [Ara-C]) in patients with acute myeloid leukemia (AML) that relapsed after standard intensive induction chemotherapy, were also reported. In 18 evaluable patients, the combination of selinexor (40 mg/m) with idarubicin/Ara-C demonstrated a 56% overall response rate, including nine patients with complete remission (CR/CRi) and one patient with a partial remission. Adverse events were manageable with standard supportive care and dose adjustments. The data from an ongoing Phase Ib clinical study of single-agent selinexor (3-80 mg/m2 oral doses) in patients with DLBCL were as of June 1, 2015 and included the following highlights: Among 28 response evaluable patients (per protocol defined as those patients on study for at least one month), the ORR was 43% and the disease control rate (stable disease or better) was 71%. Responses included four patients (14%) who achieved a complete response as confirmed by PET scan, eight patients (29%) who achieved a partial response and 8 patients (29%) with stable disease. Among 39 patients treated across all doses, the ORR was 31% and the disease control rate (stable disease or better) was 51%. Duration of response was greater than nine months. Patients with a response to selinexor (N=12), achieved OS of greater than ten months (median not reached) and PFS of 24 months which were significantly longer than those without a response (N=27; OS 3.5 months, PFS 1.2 months). The median overall survival (OS) and progression free survival (PFS) were 4.6 months and 1.7 months, respectively, for the entire study. Selinexor showed similar activity in both GCB and non-GCB subtypes of DLBCL. All data are as of April 27, 2015 and highlights include: An overall response rate of 56% was achieved based on 18 evaluable patients with three patients (17%) achieving complete remission (CR), six patients (33%) achieving complete remission with incomplete blood count recovery (CRi) and one patient (6%) achieving partial remission (PR); Ten patients (56%) received or were expected to receive either stem cell transplant or donor lymphocyte infusion; and Adverse events were manageable with standard supportive care and dose adjustments.

Karyopharm Announces the Presentation of Clinical and Preclinical Data for its Lead Product Candidate Selinexor at International Conference on Malignant Lymphoma

Karyopharm Therapeutics Inc. announced the presentation of positive clinical and preclinical data for its lead product candidate, selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export /SINE™ compound, at the 13th International Conference on Malignant Lymphoma (ICML) 2015 held June 17-20, 2015 in Lugano, Switzerland. In an ongoing Phase 1 clinical trial which included 14 evaluable, relapsed, refractory DLBCL patients with triple, double or single hit MYC, BCL2 and/or BCL6 translocations, selinexor demonstrated clinically meaningful activity with a 43% overall response rate (partial response or better). Responses included two complete responses (CR) and four partial responses (PR), while two additional patients achieved stable disease (SD). In preclinical models, selinexor demonstrated potency in double hit (DH)-DLBCL cell lines in vitro and in an aggressive patient-derived xenograft (PDX) model of triple hit (TH) DLBCL, with 84% tumor growth inhibition. DLBCL with MYC, BCL2 and/or BCL6 translocations is an area of significant unmet medical need associated with poor prognosis and no standard-of-care treatment options. Selinexor data in DH-DLBCL were described during an oral presentation by Dr. Ramiro Garzon of Ohio State University on Saturday, June 20, entitled "Selinexor Shows Marked Activity in Double-Hit Diffuse Large B Cell Lymphoma (DLBCL) in Pre-Clinical Models and in Patients with Heavily Pre-Treated Relapsed /Refractory Double-Hit DLBCL". These data from an ongoing Phase 1 clinical study of single-agent selinexor in patients with diffuse large B-cell lymphoma were as of June 1, 2015, including the following highlights: Among 14 evaluable, heavily pre-treated, patients with relapsed, refractory DLBCL with TH, DH or single-hit (SH) MYC, BCL2 and/or BCL6 translocations treated with selinexor, the overall response rate (ORR) was 43%, including two CRs and four PRs, while two patients achieved SD. Responses included three out of five patients with TH or DH DLBCL and three out of nine SH DLBCL, for a total of six out of 14 patients achieving objective responses. Toxicities were similar to the other patients in the study and no clinically significant organ dysfunction or cumulative toxicities were observed. In preclinical models, selinexor was potently cytotoxic and reduced Myc, Bcl2 and Bcl6 protein levels in DH-DLBCL cell lines in vitro and selinexor was highly active in a PDX model of TH DLBCL with 84% tumor growth inhibition.

Karyopharm Therapeutics Inc. Announces Positive Data from Solid Tumor Studies

Karyopharm Therapeutics Inc. has announced positive clinical data for Selinexor, an oral selective inhibitor of nuclear export /SINE compound, in patients with solid tumors. In an ongoing Phase II clinical trial, single-agent oral selinexor demonstrated anti-tumor activity in patients with recurrent glioblastoma, including brain penetration at clinically relevant drug levels, with a 13% overall response rate and a 38% disease control rate. In an ongoing Phase Ib clinical study of single agent oral selinexor in patients with advanced sarcomas including liposarcoma, durable activity, including longer progression free survival than last prior regimen, was demonstrated. Selinexor dosed twice weekly at 50 mg/m2 demonstrated anti-tumor activity with 13% ORR and 38% DCR in 16 surgically ineligible patients with glioblastoma that had been pretreated with temozolomide and radiation. Response data across these 16 patients were as follows: Selinexor reaches concentrations in glioblastoma tumors that are active in vitro against patient-derived glioblastoma cells; and the most common adverse events were thrombocytopenia, fatigue, anorexia, and hyponatremia. In a Phase Ib study with selinexor, a first in class selective inhibitor of nuclear export (SINE) in patients with advanced sarcomas. In 45 evaluable patients receiving single-agent selinexor dosed twice weekly, 27 patients '60%' across a variety of sarcoma types achieved stable disease. Median progression free survival for selinexor was 136 days compared with last prior regimen of 54 days in 11 liposarcoma patients with known time to progression on last prior regimen. Selinexor was generally well tolerated with supportive care for anorexia and nausea. Selinexor was dosed twice-weekly at either 30 mg/m2 '50 mg', 50 mg/m2 '80 mg' or 60 mg flat dose. On-treatment biopsies demonstrated the pharmacological activity of selinexor based upon decreased tumor cell numbers, reduced proliferative rates and increased replacement of tumor with stromal tissue compared with pre-treatment biopsies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KPTI:US $20.95 USD +0.43

KPTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KPTI.
View Industry Companies
 

Industry Analysis

KPTI

Industry Average

Valuation KPTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12,495.0x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8,380.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KARYOPHARM THERAPEUTICS INC, please visit www.karyopharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.